Highly potent and selective antagonists of such interactions have been shown to effectively disrupt the MLL1 complex with WDR5, and Menin and decrease the expression of HoxA9 and Meis‐1, inhibiting proliferation and inducing hematopoietic differentiation in MLL1 leukemia cells. Here, MEIS1 is linked to leukemia.